Results 71 to 80 of about 584,093 (236)

GLP‐1 Receptor Agonist Therapy Is Associated With Lower Risk of Lower Extremity Amputation in Adults With Type 2 Diabetes and Foot Ulcer Without Coded Peripheral Arterial Disease: A Hypothesis‐Generating Real‐World Cohort Study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To compare lower extremity amputation (LEA) risk in adults with Type 2 diabetes and diabetic foot ulcer (DFU) treated with glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) versus other glucose‐lowering therapy, and to test whether coded peripheral arterial disease (PAD) modifies this association and replicates across comparator ...
Hani Robinson   +8 more
wiley   +1 more source

The Sulfonylurea Glimepiride Regulates Intracellular Routing of the Insulin-Receptor Complexes through Their Interaction with Specific Protein Kinase C Isoforms

open access: yes, 2020
Sulfonylureas may stimulate glucose metabolism by protein kinase C (PKC) activation. Because interaction of insulin receptors with PKC plays an important role in controlling the intracellular sorting of the insulin-receptor complex, we investigated the ...
Renato Federici   +9 more
core  

INSILICO STUDIES OF OXIME PRODRUG OF GLICLAZIDE AGAINST SULPHONYLUREA RECEPTORS (SUR 1)

open access: yes, 2017
Objective: Objective of the study is to perform a molecular docking analysis of novel oxime prodrug of gliclazide against SUR1 receptor.Methods: Sulfonylurea receptors (SUR) are membrane proteins which are the molecular targets of the sulfonylurea class ...
Surendran Vijayaraj   +1 more
core   +1 more source

Changes in Metabolic and Blood Pressure Outcomes With Semaglutide Across Chronic Kidney Disease Stages: A Post Hoc Analysis of the FLOW Trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To assess changes in glycated haemoglobin (HbA1c), body weight, and systolic/diastolic blood pressure (SBP/DBP) by chronic kidney disease (CKD) and albuminuria categories in a post hoc analysis of FLOW, an international, double‐blind, randomized, phase 3b clinical trial of adults with CKD and Type 2 diabetes (T2D).
Allon N. Friedman   +10 more
wiley   +1 more source

The Ahlqvist Subphenotypes of Type 2 Diabetes: A Narrative Review of Scientific Evidence and Its Potential Contribution to Precision Diabetes

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Among several approaches, k‐means clustering has established as a widely used method to classify people with type 2 diabetes (T2D) into distinct subphenotypes, and the Ahlqvist T2D subphenotypes of Severe Insulin Deficient Diabetes (SIDD), Mild Age‐Related Diabetes (MARD), Mild Obesity Diabetes (MOD) and Severe Insulin Resistant ...
Wolfgang Landgraf   +3 more
wiley   +1 more source

Sulfonylurea herbicides

open access: yes, 1991
Available from British Library Document Supply Centre- DSC:q91/15871(Sulfonylurea) / BLDSC - British Library Document Supply CentreSIGLEGBUnited ...
Smith, C   +1 more
core  

Cardiovascular Outcomes of Insulin Degludec Versus Insulin Glargine in Trial‐Eligible and Ineligible Populations: A DEVOTE‐Inspired Target Trial Emulation Using the Swedish National Diabetes Register

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To compare cardiovascular outcomes associated with the initiation of insulin degludec versus insulin glargine using a target trial emulation approach in nationwide real‐world data. Materials and Methods We conducted a nationwide observational cohort study using Swedish health registers, including the National Diabetes Register ...
Thomas Nyström   +16 more
wiley   +1 more source

Neuropsychiatric Outcomes Associated With GLP‐1 Receptor Agonist Use in Medicare Beneficiaries With Type 2 Diabetes: Variation by Treatment Pattern and Obesity Status

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Glucagon‐like peptide‐1 (GLP‐1) receptors are expressed in brain regions governing mood, reward and stress, yet the neuropsychiatric effects of GLP‐1 receptor agonist (GLP‐1 RA) therapy remain poorly characterized. We estimated associations between GLP‐1 RA use and neuropsychiatric disorders and variation by obesity status and treatment ...
Seo Hyon Baik   +4 more
wiley   +1 more source

Reduction of Sulfonylurea with the Initiation of Basal Insulin in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Undergoing Long-Term Sulfonylurea-Based Treatment [PDF]

open access: yes, 2016
BackgroundThere were a limited number of studies about β-cell function after insulin initiation in patients exposed to long durations of sulfonylurea treatment.
Jeong-Ah Shin   +7 more
core   +1 more source

Efficacy and Safety of CagriSema in Type 2 Diabetes: A Dose‐ and Comparator‐Specific Systematic Review and Bayesian Meta‐Analysis

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background CagriSema combines cagrilintide with semaglutide and may improve glycaemic control and body weight in Type 2 diabetes. We evaluated its dose‐ and comparator‐specific efficacy and safety. Methods PubMed, Embase, CENTRAL and ClinicalTrials.gov were searched through 30 June 2026 for randomized controlled trials.
Chia Siang Kow   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy